Answers are grounded in this paper and cite their sources.
Epilepsy is a non-communicable central nervous system (CNS) disease that accounts for approximately 0.8–1.2 % of the global population at any time. The hyper-activities of gamma butyric acid aminotransferase (GABAAT) enzyme have been confirmed to be largely responsible for seizure/epilepsy. Because of this special function, the GABAAT enzyme has been the main target of many anti-epilepsy drugs (AEDs). To date, many discovered AEDs have not eradicated this neurological disease. Since experimental determinations of modern drugs are usually costly and sometimes non-eco-friendly, in-silco quantitative structure-activity relationship (QSAR)-machine learning, docking and pharmacokinetics (PMK) techniques were used to design and test the oral bio-availabilities of all the designed AEDs. QSAR models were generated, and the predictive properties of R2int = 0.9827, R2ext = 0.9407, and R2adj of 0.9667 indicate the evidence that the developed model was not by chance. Six (6) new AEDs were newly designed, and they were found to have better anti-epileptic activities values of 2.146799, 2.224866, 2.31479, 2.450313, 2.301474, and 2.618303 than the standard AED, Vigabatrin (0.40672). Also, the docked new compounds shows excellent binding energies of −127.001, −129.071, −130.515, −126.881, −130.771, and −126.974 Kcal/mol compared to the referenced AED (−76.9173 Kcal/mol). The PMK and absorption, distribution, metabolism, excretion, and toxicity (ADMET) investigations also revealed that all the designed compounds were found to be bio-available for human administration. ‘Therefore, the newly designed analogues (AEDs) could be considered as potential drug candidates for the treatment of epilepsy.
No takes yet. Share an insight, caveat, or question.
Abdulfatai et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: